お知らせ • May 12
Windtree Therapeutics, Inc. Announces Presentation of Preclinical Data on Istaroxime and A Selective Serc2a Activator At the European Society of Cardiology Heart Failure Conference
Windtree Therapeutics, Inc. announced istaroxime and a selective SERCA2a activator data furthering the demonstration of reduction in arrythmias in an animal study. The data is in a poster presentation at the European Society of Cardiology Heart Failure Conference. Windtree Therapeutics will present an e-poster at the ESC Heart Failure Congress on the impact of istaroxime and its metabolite analog (CVie216) in activating sarcoplasmic reticulum (SR) Ca2+-ATPase, commonly known as SERCA2a, to reduce Ca2+-dependent arrhythmias in the STZ rat model induced by ischemia-reperfusion. The Company may, in some cases, use terms such as "predicts," "bel believes," "pot potential," "proposed," "continue," "estimates," "anticipates," "ex expects," "ex expects," " plans," " plans," "intends," "could," " might," "will," "will," " should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidate, and the Company's ability to service those markets; the company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in Israel and Israel and Israel and Israeli, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial.